John H. Tinney, Jr.

I'll research this attorney's background and the tracked case.

Let me investigate the tracked case and the intervenor role more closely.

Let me verify the intervenor role and check for any broader patent/IP practice.

John H. "Jack" H. Tinney, Jr. — Hendrickson & Long, PLLC (Charleston, WV)

Specialty / focus. Tinney is a general commercial and trial litigator, not a patent specialist. His published practice areas are professional liability, product liability, business and commercial litigation, construction, insurance/bad faith, appellate work, and white-collar criminal defense. His single tracked patent matter is in the biologics/pharma space rather than software, Wi-Fi, or mechanical arts: the In re Aflibercept Patent Litigation MDL (N.D. W. Va., No. 1:24-md-3103), part of Regeneron's BPCIA campaign over EYLEA (aflibercept) against biosimilar makers. His role there was localized — West Virginia counsel, not merits-side patent advocacy.

Side preference. The tracked data show one appearance, on the defense/intervenor side (0 plaintiff, 0 NPE/PAE work). His actual engagement was as local counsel for Amgen USA, Inc. as a limited-purpose intervenor in Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. (N.D. W. Va., No. 1:22-cv-00061). Amgen moved to intervene in May 2023 solely to assert First Amendment and common-law public access rights and to unseal documents, not to litigate infringement. His patent-caseload footprint is therefore narrow and does not suggest a plaintiff-side or NPE practice.

Firm context. Tinney has been with Hendrickson & Long since February 2016. Before that he founded The Tinney Law Firm, PLLC (2001–2016), and earlier served as an Assistant U.S. Attorney for the Southern District of West Virginia and as a law clerk to Judge Robert B. King on the Fourth Circuit. He is not in-house. (Note: a separate, older Charleston attorney also named John H. Tinney practiced at Spilman, Thomas & Battle; do not conflate the two.)

Notable matters and PTAB. The most prominent matter tied to him is the aflibercept biosimilar litigation, where the district court denied Regeneron a preliminary injunction against Amgen and the Federal Circuit affirmed (Regeneron Pharms., Inc. v. Mylan Pharms. Inc., 130 F.4th 1372 (Fed. Cir. 2025)) on non-infringement of U.S. Patent 11,084,865. Tinney's contribution was the collateral sealing/public-access intervention; he is not identified in the appellate merits briefing or argument. There is no indication he appears in IPR/PGR proceedings before the PTAB.

Bar / education. J.D., Wake Forest University School of Law, 1995; B.A. (history), cum laude, Washington and Lee University, 1992. Admitted in West Virginia (1995), the Fourth Circuit (1999), and the Northern and Southern Districts of West Virginia.

Caveat: with only one tracked appearance and no firm bio describing a patent practice, this profile reflects a West Virginia commercial litigator who was retained as local counsel in a pharma patent MDL, not an established patent-litigation practice.